Stocks · Health care · Biological Products, (No Diagnostic Substances)

Kalaris Therapeutics, Inc.

KLRS Clue Score19
United States Fiscal year ends December CIK 0001754068 Results filed 11 Aug 2026

What the insiders did No buying or selling

By person

8 insiders · 0 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Diana Brainard
Chief Executive Officer
—
—
—
723,363
$3.49M
−1.2%
Napoleone Ferrara
Director
—
—
—
504,000
$2.43M
—
Edward Miller
General Counsel
—
—
—
352,865
$1.70M
−0.3%
Samir Chandrakant Patel
Director
—
—
—
352,800
$1.70M
—
Vikas Sinha
See Remarks
—
—
—
49,129
$237.29K
−8.6%
Srinivas Akkaraju
Director
—
—
—
19,408
$93.74K
—
Matthew Feinsod
Chief Medical Officer
—
—
—
4,030
$19.46K
—
Brett R Hagen
Chief Accounting Officer
—
—
—
0
$0.00
−100.0%

No percentages here. This company's share count has moved by a factor of 4.7 over the window, from 5,043,357 to 23,804,981 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.